4 results
The overall objective of this phase I/II three-part study is to evaluate the benefit of 12 weeks once daily dosing with ASP9521 in a population of patients with metastatic castrate resistant prostate cancer (CRPC) who have failed one or more lines…
The primary objective of this study is to evaluate the course of plasma- and urinary levels of carnitine and all carnitine esters during the first cycle of treatment with oxaliplatin-based chemotherapy and intravenous carnitine supplementation. The…
The primary objectives are to investigate which determinants (primarily carnitine status) determine the effect of carnitine supplementation on metabolic flexibility and insulin sensitivity in patients with type 2 diabetes. Furthermore, a secondary…
primary objectives:* Part 1 (dose escalation): To determine therecommended Phase 2 dose(s) (RP2D[s]) forTAR-210* Part 2 (dose expansion): To determine thesafety of TAR-210 administered at theRP2D(s)for up to 12 monthsSecondary objectives (Parts 1…